Certara (NASDAQ:CERT) Insider Sells 51,224 Shares

Key Points

• Insider Leif Pedersen sold 51,224 shares of Certara at an average price of $10.92, totaling over $559,000, which decreased his holdings by 40.91%.
• Certara's stock recently traded at $10.93 with a market cap of approximately $1.76 billion and a P/E ratio of 218.64.
• The company reported $0.07 earnings per share in its last quarter, missing analysts' expectations, but achieved a 12.1% increase in revenue year-over-year.

Certara, Inc. (NASDAQ:CERT - Get Free Report) insider Leif Pedersen sold 51,224 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. This represents a 40.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Certara Stock Performance

CERT traded up $0.68 on Thursday, reaching $10.93. The stock had a trading volume of 1,876,619 shares, compared to its average volume of 1,685,549. The business's 50-day moving average price is $10.74 and its two-hundred day moving average price is $11.30. The company has a market cap of $1.76 billion, a P/E ratio of 218.64 and a beta of 1.43. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%.The firm had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same period in the previous year, the company earned $0.07 earnings per share. The company's revenue was up 12.1% compared to the same quarter last year. Sell-side analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Institutional Trading of Certara

Hedge funds and other institutional investors have recently bought and sold shares of the business. AdvisorNet Financial Inc acquired a new position in Certara in the second quarter valued at approximately $25,000. Versant Capital Management Inc lifted its position in shares of Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after buying an additional 1,866 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Certara in the 1st quarter valued at $31,000. Wells Fargo & Company MN grew its position in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares during the last quarter. Finally, AlphaQuest LLC acquired a new stake in Certara during the 1st quarter worth $39,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CERT has been the topic of a number of research analyst reports. UBS Group dropped their price target on shares of Certara from $17.50 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Morgan Stanley initiated coverage on shares of Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 target price on the stock. KeyCorp dropped their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a report on Monday, July 14th. Finally, Zacks Research raised Certara from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.14.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.